Clinical trials: Hepatic Lesion, open to volunteers
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc)
Pragmatic RCT of AI-Assisted Reading for Malignant Hepatic Lesions on CE-CT
The purpose of this multicenter pragmatic randomized controlled trial is to determine whether AI-assisted interpretation of multiphasic liver contrast-enhanced computed tomography (CE-CT) is non-inferior to standard radiology…
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Hepatic Metastasis, Hepatic Hemangioma
- Trial name
- NCT07768085
- Testing
- AI-assisted abdominal CE-CT reporting, Standard abdominal CE-CT reporting without AI assistance
- Where
- China
- Volunteers
- 40,000 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Liver Lesion
Gadopiclenol vs Gadoxetate MRI for Liver Lesions
The overall purpose of this study is to establish noninferiority of gadopiclenol MRI compared to gadoxetate MRI in terms of image quality and lesion detection/conspicuity in patients undergoing clinically indicated liver MRI in a…
- Trial name
- NCT06596616
- Testing
- Radiology, Gadopiclenol
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hepatocellular Carcinoma (HCC) Prognosis, Contrast-enhanced Ultrasound
A Comparative Study on the Diagnostic Efficacy of Ultrasound Contrast LI-RADS Grading and the German ESCULAP Standards for the Diagnosis of Recurrent Hepatic Mass Lesions After Hepatocellular Carcinoma Surgery
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide, with a significantly increased incidence among patients with liver diseases.
- Trial name
- NCT07600346
- Testing
- Contrast-Enhanced Ultrasound
- Volunteers
- 105 people
- Sponsor
- The First Hospital of Jilin University
Focal Liver Lesion
The Role of Ceus in the Characterization of Focal Liver Lesions Indeterminate to Second-level Methods
The primary objective of the study is to determine the accuracy of CEUS in characterizing (as benign or malignant) focal liver lesions for which CT, MRI and/or PET have not been conclusive.
- Trial name
- InFoLIL (NCT06876805)
- Testing
- CEUS or Contrast enhanced Ultrasound
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hepatic Malignant Tumors, Hepatic Perfusion Disorders
Correlation Between CEUS Identification of Nodular HPD on CE-MRI and Hepatic Malignant Lesions
Hepatic malignant tumors are a category of diseases with high incidence and mortality rates worldwide, including various types such as primary hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and liver…
- Trial name
- NCT06816212
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
HCC, Hepatocellular Carcinoma
Y-90 Treatment Response Using Transarterial Radioembolization
This prospective clinical study will examine the ability of contrast-enhanced ultrasound (CEUS) to assess the treatment response of hepatocellular carcinoma (HCC) to transarterial radioembolization (TARE).
- Conditions
- HCC, Hepatocellular Carcinoma, Liver Cancer, Hepatic Neoplasm
- Trial name
- TARE (NCT07145801)
- Testing
- Lumason, Sonazoid
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Thomas Jefferson University
Hepatoma
The Diagnostic Efficacy and Lesion Detection Advantages of 18F-FDG PET/CT and Enhanced MRI in Hepatic Malignancies
Liver disease is a major challenge for global public health, covering a wide range from mild liver dysfunction to serious diseases such as cirrhosis and liver cancer.
- Trial name
- NCT06700564
- Testing
- PET scan of FDG
- Volunteers
- 60 people
- Sponsor
- Shanghai East Hospital